In Vivo Silencing of the Transcription Factor IRF5 Reprograms the Macrophage Phenotype and Improves Infarct Healing
Gabriel Courties(Harvard University), Matthias Nahrendorf(Massachusetts General Hospital), Timo Heidt(Harvard University), Tatiana I. Novobrantseva(Alnylam Pharmaceuticals (United States)), Yoshiko Iwamoto(Harvard University), Derrick Jeon(Harvard University), Filip K. Świrski(Allen Institute for Brain Science), Daniel G. Anderson(Massachusetts Institute of Technology), Gregory R. Wojtkiewicz(Harvard University), Peter Libby(Harvard University), Anna Borodovsky(Brigham and Women's Hospital), Boris Klebanov(Karyopharm Therapeutics (United States)), Partha Dutta(University of Pittsburgh), Ralph Weissleder(Massachusetts General Hospital), Benoit Tricot(Harvard University), Matthew Sebas(Harvard University), Jessica Truelove(Massachusetts General Hospital), Kevin Fitzgerald(Epsilon Systems (United States)), Hendrik B. Sager(German Centre for Cardiovascular Research)
Cited by 280
Related Papers
A clearer vision for in vivo imaging
|Nature Biotechnology|2001|3.8k
Inflammation in Atherosclerosis
|Arteriosclerosis Thrombosis and Vascular Biology|2012|3.7k
Knocking down barriers: advances in siRNA delivery
|Nature Reviews Drug Discovery|2009|3.1k
Atherosclerosis
|Nature Reviews Disease Primers|2019|3k
From Vulnerable Plaque to Vulnerable Patient
|Circulation|2003|2.7k